MedTrace Logo

Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients

NCT02065999 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2024-03-06

No results posted yet for this study

Summary

This is a multi-centre prospective longitudinal cohort study with the aim of collecting and storing clinical data, patient blood, DNA and PBMCs to examine outcomes related to drug resistance, drug monitoring and host genetics in the era of directly acting antiviral drugs for hepatitis C therapy.

Conditions

  • Chronic Hepatitis C Infection

Sponsors & Collaborators

  • The University of New South Wales

    collaborator OTHER

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Kirby Institute

    lead OTHER_GOV

Principal Investigators

  • Gail Dr Matthews, MBChB, MRCP (UK), FRACP, PhD · The University of New South Wales

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2022-06-30
Completion
2022-06-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02065999 on ClinicalTrials.gov